IPP Bureau
Govt. to improve availability of infrastructure and trained manpower for organ transplantation
By IPP Bureau - September 01, 2024
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
Mitsubishi Chemical's clinical study demonstrates effectiveness of probiotic on intestinal environment
By IPP Bureau - September 01, 2024
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Biocon Pharma receives USFDA approval for daptomycin
By IPP Bureau - September 01, 2024
The approval further adds to Biocon’s portfolio of complex drug products
Zydus receives warning letter from USFDA for Jarod injectables manufacturing facility
By IPP Bureau - August 31, 2024
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
Thyrocare to acquire diagnostic and pathological services business of Vimta Labs
By IPP Bureau - August 31, 2024
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
DKSH partners with Hasten Biopharmaceutical’s growth in Thailand
By IPP Bureau - August 31, 2024
Indian doctor participates in Jordan’s first robotic radical hysterectomies
By IPP Bureau - August 31, 2024
Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan
By IPP Bureau - August 30, 2024
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Vaishali Pharma Ltd recommends 1:1 bonus issue and 1:5 stock split
By IPP Bureau - August 30, 2024
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Natco Pharma announces submission of TABRECTA to USFDA
By IPP Bureau - August 30, 2024
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Ayurvedic Whole System effective in Managing Rheumatoid Arthritis: Study
By IPP Bureau - August 30, 2024
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Suven Life Sciences announces FDA acceptance of investigational new drug
By IPP Bureau - August 30, 2024
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Bayer starts Phase III trial in non-small cell lung cancer
By IPP Bureau - August 30, 2024
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Bayer awards incubator opportunity to Genvor
By IPP Bureau - August 30, 2024
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
